 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.
The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness.
The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel.
On Wednesday, February 10, Vanda Pharmaceuticals reported 4th Quarter December 2020 earnings of $0.15 per share on revenue of $67.7 million. The consensus earnings estimate was $0.10 per share on revenue of $64.0 million. Revenue grew 11.0% on a year-over-year basis.
The company said it expects 2021 revenue of $270.0 million to $300.0 million. The current consensus revenue estimate is $279.4 million for the year ending December 31, 2021.
Following a strong earnings report, this small market-cap stock should see an increase in share prices. The company recently received FDA approval to proceed with investigational new drug VSJ-110 for allergic conjunctivitis.
Entry point: $18.70
52-week trade range: $4.29 - $37.00
Stop/Loss: $17.75
Target Price: $20.50
